Medications

Ozempic vs. Wegovy: What's the Difference? (Same Drug, Different Uses)

GLP-1 Companion · 7 min read

One of the most common questions in the GLP-1 space is: what is the difference between Ozempic and Wegovy? The short answer is that both medications contain semaglutide and are manufactured by Novo Nordisk. The longer answer involves important differences in FDA-approved indications, dosing, insurance coverage, and how each is prescribed.

Same Active Ingredient, Different Labels

Both Ozempic and Wegovy deliver semaglutide—a GLP-1 receptor agonist—via once-weekly subcutaneous injection. The molecule, the mechanism of action, and the manufacturer are identical. The reason two separate brands exist comes down to FDA regulatory requirements: a drug must be approved for each specific indication through separate clinical trials and applications.

FDA-Approved Indications

• Ozempic: Approved to improve blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise. Also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
• Wegovy: Approved for chronic weight management in adults with a BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related condition. Also approved for adolescents aged 12 and older with obesity. Additionally approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with obesity or overweight and established cardiovascular disease.

Dosing Differences

This is where the two brands diverge in a clinically meaningful way. Wegovy is dosed higher than Ozempic, which contributes to greater weight loss in clinical trials.

Ozempic Dosing

1. 0.25 mg weekly for 4 weeks (initiation)
2. 0.5 mg weekly (first maintenance dose)
3. 1 mg weekly (if additional glycemic control needed)
4. 2 mg weekly (maximum dose, for additional glycemic control)

Wegovy Dosing

1. 0.25 mg weekly for 4 weeks
2. 0.5 mg weekly for 4 weeks
3. 1 mg weekly for 4 weeks
4. 1.7 mg weekly for 4 weeks
5. 2.4 mg weekly (maintenance dose)

The key difference: Ozempic's maximum dose is 2 mg, while Wegovy goes up to 2.4 mg. Additionally, Wegovy has two dose steps (1.7 mg and 2.4 mg) that Ozempic does not offer. This higher ceiling dose is one reason Wegovy produces more weight loss in clinical studies.

Weight Loss Comparison

While both medications cause weight loss, the degree differs due to the dosing difference and the populations studied.

• Ozempic (at 1 mg): Patients with type 2 diabetes lost an average of 4.5–6.5 kg (10–14 lbs) in clinical trials over 30–56 weeks.
• Ozempic (at 2 mg): Up to approximately 6.9 kg (15 lbs) of weight loss.
• Wegovy (at 2.4 mg): Patients without diabetes lost an average of 15% of body weight (approximately 33 lbs) over 68 weeks in the STEP 1 trial.

Even though Ozempic is not approved for weight loss, many patients experience significant weight reduction. However, Wegovy at the higher 2.4 mg dose consistently produces greater weight loss in clinical studies.

Insurance and Cost

Insurance coverage is one of the most important practical differences between Ozempic and Wegovy, and often determines which medication a patient can access.

• Ozempic: Generally well-covered by most commercial insurance plans and Medicare Part D for patients with a type 2 diabetes diagnosis.
• Wegovy: Coverage is less consistent. Many insurance plans exclude weight-loss medications, and Medicare Part D historically has not covered anti-obesity drugs (though legislation is evolving).
• List price: Both medications cost roughly $900–$1,350 per month without insurance.
• Savings programs: Novo Nordisk offers manufacturer savings cards for eligible commercially insured patients for both brands.

Can You Use Ozempic for Weight Loss?

Many providers prescribe Ozempic off-label for weight loss, particularly when a patient cannot access Wegovy due to cost, insurance restrictions, or supply shortages. This is a common and legally acceptable practice, though it means the maximum available dose is 2 mg rather than 2.4 mg. If weight loss is your primary goal and you can access it, Wegovy at its higher dose is the more evidence-supported option.

Which One Should You Choose?

The best choice depends on your diagnosis, insurance coverage, and treatment goals.

• If you have type 2 diabetes: Ozempic is the natural starting point, as it is approved for your condition and typically well-covered by insurance.
• If your primary goal is weight loss (without diabetes): Wegovy is the FDA-approved option and offers a higher maximum dose.
• If Wegovy is unavailable or unaffordable: Ozempic off-label may be a reasonable alternative—discuss with your provider.
• If you have both diabetes and obesity: Either may work; your provider will consider which indication optimizes your insurance coverage and clinical needs.

Can You Switch Between Ozempic and Wegovy?

Yes, switching is possible since both are semaglutide. Your provider can transition you from one to the other at an equivalent dose without restarting the escalation schedule. For example, a patient on Ozempic 1 mg could switch to Wegovy 1 mg and continue escalating from there. However, switching should always be coordinated with your healthcare team to ensure proper dosing and insurance authorization.

The Bottom Line

Ozempic and Wegovy are the same molecule—semaglutide—packaged for different FDA-approved purposes. Ozempic is designed for type 2 diabetes with a maximum dose of 2 mg, while Wegovy targets chronic weight management with a higher 2.4 mg dose. Your diagnosis, insurance situation, and health goals should guide the choice. Speak with your healthcare provider to determine the best path forward.

Sources

• Ozempic (semaglutide) Prescribing Information. Novo Nordisk.
• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.